Literature DB >> 12095461

Neuropharmacologic targets and agents in fibromyalgia.

Rie Suzuki1, Anthony H Dickenson.   

Abstract

Chronic widespread pain is a primary feature of fibromyalgia and is a symptom that is poorly managed in many patients. In addition, patients often experience fatigue, sleep disturbances, and anxiety. Its etiology is largely unknown. The successful clinical management of this syndrome relies on a multidisciplinary approach, employing pharmacologic and nonpharmacologic treatments. Clinical evidence on the symptoms and characteristics of fibromyalgia suggests a central mechanism behind the pathogenesis of this syndrome. It is likely that drugs with central actions will prove to be effective against a number of symptoms. This article aims to outline some of the potential spinal pharmacologic targets that may be used to treat this condition.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12095461     DOI: 10.1007/s11916-002-0047-0

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  43 in total

Review 1.  Fibromyalgia syndrome: a new paradigm for differential diagnosis and treatment.

Authors:  D M Brady; M J Schneider
Journal:  J Manipulative Physiol Ther       Date:  2001-10       Impact factor: 1.437

Review 2.  Calcium ions, active zones and synaptic transmitter release.

Authors:  S J Smith; G J Augustine
Journal:  Trends Neurosci       Date:  1988-10       Impact factor: 13.837

3.  Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis.

Authors:  Henning Vaerøy; Robert Helle; Øystein Førre; Erik Kåss; Lars Terenius
Journal:  Pain       Date:  1988-01       Impact factor: 6.961

4.  Relationship of substance P, 5-hydroxyindole acetic acid and tryptophan in serum of fibromyalgia patients.

Authors:  M J Schwarz; M Späth; H Müller-Bardorff; D E Pongratz; B Bondy; M Ackenheil
Journal:  Neurosci Lett       Date:  1999-01-15       Impact factor: 3.046

5.  A randomized controlled trial of citalopram in the treatment of fibromyalgia.

Authors:  Jesper Nørregaard; Helge Volkmann; Bente Danneskiold-Samstøe
Journal:  Pain       Date:  1995-06       Impact factor: 6.961

Review 6.  The induction of pain: an integrative review.

Authors:  M J Millan
Journal:  Prog Neurobiol       Date:  1999-01       Impact factor: 11.685

7.  Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial.

Authors:  M Backonja; A Beydoun; K R Edwards; S L Schwartz; V Fonseca; M Hes; L LaMoreaux; E Garofalo
Journal:  JAMA       Date:  1998-12-02       Impact factor: 56.272

8.  Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial.

Authors:  M Rowbotham; N Harden; B Stacey; P Bernstein; L Magnus-Miller
Journal:  JAMA       Date:  1998-12-02       Impact factor: 56.272

9.  Response of chronic neuropathic pain syndromes to ketamine: a preliminary study.

Authors:  Miroslav Backonja; George Arndt; Kathy A Gombar; Bill Check; Mary Zimmermann
Journal:  Pain       Date:  1994-01       Impact factor: 6.961

10.  Continuous subcutaneous administration of the N-methyl-D-aspartic acid (NMDA) receptor antagonist ketamine in the treatment of post-herpetic neuralgia.

Authors:  Per Kristian Eide; Audun Stubhaug; Ivar Øye; Harald Breivik
Journal:  Pain       Date:  1995-05       Impact factor: 6.961

View more
  1 in total

1.  The importance of the descending monoamine system for the pain experience and its treatment.

Authors:  Lucy A Bee; Anthony H Dickenson
Journal:  F1000 Med Rep       Date:  2009-10-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.